Carly S. Filgueira, PhD
Assistant Research Professor of Nanomedicine, Institute for Academic Medicine
Department of Nanomedicine
Department of Cardiovascular Surgery
Adverse effects are critical problems associated with systemic drug delivery and, therefore, research is shifting towards local, sustained release approaches. We present several delivery platforms to aid in the continuous, low-dose, constant administration of therapeutics to treat multiple indications. Technologies include the use of nanochannel membranes for sustained release of therapeutics to treat metabolic syndrome as well as induce bone growth, intratumoral delivery of gold nanoparticles for treatment of lung cancer, and intrapericardial delivery of polymeric nanoformulations for heart failure. The described implantable nanochannel membrane offers an alternative to conventional daily administration, which faces compliance issues in clinical settings.
Thursday, August 29 at 12:00pm to 1:00pm
Houston Methodist Research Institute, Ernest H. Cockrell Boardroom (R2-311)
6670 Bertner Avenue